As of Nov 19, 2026, 0 of 2 active firms rate HSTM a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HSTM EPS & revenue forecast
EPS · NEXT QUARTER
$0.18
Range $0.17 – $0.20 · 4 analysts · -8% YoY
Next period, 4 analysts expect HealthStream Inc to earn $0.18 a share (range $0.17 – $0.20), versus $0.20 a year earlier. Full-year consensus is $0.81, growing to $0.92 the year after.
REVENUE · NEXT QUARTER
$84.6M
Range $84.4M – $84.9M · 4 analysts · +4% YoY
Revenue is expected to reach $84.6M (range $84.4M – $84.9M), +4.2% year-over-year. Full-year consensus is $332.0M, rising to $346.5M next year.
Top analysts covering HealthStream Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HSTM.
#1
Richard Close
Canaccord Genuity · Rank #249
Neutral
$27.00-0.9% to target
Overall win rate
37%
+ Follow
#2
Constantine Davides
JMP Securities · Rank #454
Neutral
No targeton HSTM
Overall win rate
32%
+ Follow
#3
GM
Gene Mannheimer
Freedom Capital Markets
Neutral
$36.00+32.2% to target
Coverage
—
+ Follow
#4
EM
Eugene Mannheimer
Freedom Capital Markets
Neutral
$36.00+32.2% to target
Coverage
—
+ Follow
#5
RD
Ryan Daniels
William Blair
Buy
No targeton HSTM
Coverage
—
+ Follow
HSTM stock forecast FAQ
What is HSTM's average 12-month price target?+
The 2 active firms with a live target average $31.50 for HealthStream Inc over the next 12 months, ranging from a $36.00 high to a $27.00 low, as of Nov 19, 2026.
Is HSTM stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for HSTM?+
The Street-high target is $36.00 (Freedom Capital Markets), and the Street-low is $27.00 (Canaccord Genuity). The average of all 2 active-firm targets is $31.50.
How many active Wall Street firms cover HSTM?+
2 active firms have a recognized rating on HealthStream Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HSTM?+
Among analysts who currently cover HSTM, Richard Close of Canaccord Genuity has the strongest overall Quantellect track record (Rank #249). Their current call is Neutral with a $27.00 target.
What is HealthStream Inc's projected EPS for next quarter?+
The consensus estimate is $0.18 per share (range $0.17 – $0.20) across 4 analysts. Full-year EPS is projected at $0.81, rising to $0.92 the following year.
How much revenue is HealthStream Inc expected to report next quarter?+
Consensus revenue is $84.6M (range $84.4M – $84.9M). Full-year revenue is projected at $332.0M, growing to $346.5M next year.
Have analysts been upgrading or downgrading HSTM lately?+
As of Nov 19, 2026, 0 of 2 active firms rate HSTM a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HSTM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.